Phase 3 trial

words.Eli Lilly’s Phase 3 BRUIN CLL‑314 trial showed pirtobrutinib, a reversible BTK inhibitor, achieved a non‑inferior ORR of 87 % versus 78.5 % for ibrutinib in CLL/SLL patients, meeting its primary endpoint. Early PFS trends favored pirtobrutinib, with a 43 % reduction in progression/death risk overall and 76 % in treatment‑naïve patients. The drug demonstrated a safer profile—lower atrial fibrillation (2.4 % vs. 13.5 %) and hypertension (10.6 % vs. 15.1 %). FDA‑approved after covalent BTK failure, it now seeks frontline indication, potentially reshaping the BTK inhibitor market.

BioNTech and OncoC4 presented non‑pivotal Phase 3 PRESERVE‑003 data for the selective T‑reg modulator gotistobart (BNT316/ONC‑392) in previously treated metastatic squamous NSCLC. With 45 patients on gotistobart and 42 on docetaxel, median overall survival was not reached versus 10 months, and 12‑month OS rates were 63.1 % versus 30.3 %. The hazard ratio for death was 0.46 (95 % CI 0.25–0.84; p = 0.0102). Grade ≥ 3 treatment‑related adverse events occurred in 42.2 % of gotistobart patients. The drug holds FDA Fast Track status.

Abivax (ABVX) reported positive Phase 3 ABTECT trial results for obefazimod in ulcerative colitis. A pooled analysis showed a 16.4% placebo-adjusted clinical remission rate at Week 8 with the 50mg dose, meeting the FDA primary endpoint. Trials enrolled a refractory population, including patients who failed advanced therapies or JAK inhibitors. No new safety signals for serious infections or malignancies were reported. Headache and nausea were common adverse events. Analysts believe efficacy in the difficult-to-treat patient group could position obefazimod favorably in the market.

IO Biotech (IOBT) will release topline results from its Phase 3 trial (IOB-013/KN-D18) of Cylembio, an immune-modulatory cancer vaccine, in combination with KEYTRUDA® for advanced melanoma on August 11, 2025. A conference call and live webcast will detail the data comparing Cylembio plus KEYTRUDA® versus KEYTRUDA® alone as a first-line treatment. The trial focuses on patients with unresectable or metastatic melanoma. A replay will be available on the company website.

Innovent Biologics’ dual GCG/GLP-1 agonist mazdutide demonstrated significant weight loss (14.84% vs. 0.47% placebo) in a Phase 3 trial (GLORY-1) with 610 Chinese adults with obesity over 48 weeks, published in *NEJM*. Over 50% achieved ≥15% weight reduction, alongside improved cardiovascular and liver health. Safety aligned with GLP-1 therapies, with transient gastrointestinal effects. This marks the first NEJM-published metabolic therapy trial from China, signaling the nation’s rise in drug innovation. Experts emphasized mazdutide’s potential in addressing China’s obesity crisis under “Healthy China 2030.” Partnerships with Eli Lilly and ongoing trials aim to expand its use in metabolic diseases.

Mineralys Therapeutics’ lorundrostat, a novel aldosterone synthase inhibitor, demonstrated strong Phase 3 results in treating resistant hypertension across 1,000+ patients. The trial showed sustained systolic reductions of 19.0 mmHg (11.7 mmHg vs placebo) at 12 weeks and a favorable safety profile with 0.1% serious adverse events. Exceeding FDA efficacy benchmarks, the therapy achieved dual Phase 3 validation and potentially reduces cardiovascular risk by 20-40%. With patent protection through 2041 and a projected $10B+ market opportunity, Mineralys plans Q1 2026 regulatory submission. The company’s $1.2B market cap signals growth potential amid rising global demand for precision hypertension treatments.

Savara Inc. announced positive Phase 3 trial results for molgramostim in autoimmune pulmonary alveolar proteinosis (aPAP) at ATS 2025. In 157 patients, the therapy significantly reduced radiological surfactant burden (mean GGO score decrease 2.1 vs. 1.1; P=0.0004) and need for rescue whole-lung lavage (7.4% vs. 13.3%). Molgramostim improved respiratory quality of life metrics (St. George’s Respiratory Questionnaire, P=0.0084) and reduced breathing difficulties (P=0.0305 and P=0.0049 at Weeks 24/48). By addressing impaired GM-CSF signaling, this inhaled therapy could redefine aPAP treatment, offering a non-invasive alternative to current procedures. Trial data supports future regulatory submissions for rare disease approval pathways.